Integrated Products
Chemistry Products
Immunodiagnostic Products
Lab Automation
Menu of assays
Data management
Integrated Product Portfolio
Assay Menu and Lab Management Solutions
Chemistry and immunodiagnostics
Transfusion Medicine
Support
P.A.C.E. CE contact hours: .5 hours
Heart failure is a leading cause of death and disability in the United States. ENTRESTO®, a novel heart failure treatment, has been shown to increase life expectancy and reduce hospitalizations. As more patients are prescribed this medication, it is important to understand the potential implication in the clinical laboratory.
Dr. Jaeger reviews published data showing how levels of the biomarker BNP are affected in patients taking ENTRESTO and discusses the potential impact on risk assessment and clinical decision-making. Hear how you can lead change in your lab to support the use of this guideline-recommended medication that is helping patients with heart failure live longer.
ENTRESTO is a registered trademarks of Novartis AG.
References: Am Health Drug Benefits. 2015 Sep; 8(6): 330–334. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636283/ Accessed July 1, 2019.
Jared Jaeger, Ph.D. Clinical Science Liaison, Ortho Clinical Diagnostics
Enjoy unlimited access to the very best insights across the diagnostic community including industry reports and regular webinars from thought leaders.
Sign up for Free!